Title : Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance.

Pub. Date : 2022

PMID : 35431974






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Despite the initial benefit from treating ERBB2-positive breast cancer with tyrosine kinase inhibitor lapatinib, resistance develops inevitably. Lapatinib erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 Since the expression of protein tyrosine phosphatase receptor-type O (PTPRO), a member of the R3 subfamily of receptor protein tyrosine phosphatases (PTPs), is inversely correlated with the aggressiveness of multiple malignancies, we decided to explore the correlation between PTPRO and lapatinib resistance in ERBB2-positive breast cancer. Lapatinib erb-b2 receptor tyrosine kinase 2 Homo sapiens